Lactobacillus acidophilus ： Irritable Bowel Syndrome (IBS)
B エビデンス 少なくとも1件のランダム化試験がこれを支持しており、おおむね一貫した結果が得られています。Improves intestinal transit time and reduces constipation symptoms in IBS-C. Fecal pH decreases indicating improved fermentation. Best evidence for L. acidophilus NCFM strain.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Dacidophilus\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
結論
Improves intestinal transit time and reduces constipation symptoms in IBS-C. Fecal pH decreases indicating improved fermentation. Best evidence for L. acidophilus NCFM strain.
Key Study Findings
Randomized Controlled Trial
n=200
12 weeks
Double-blind
Probiotic Blend of Lactobacillus acidophilus LA-5 and Bifidobacterium animalis ssp. Lactis BB-12 in Non-constipated Irritable …
Dose: None
vs: placebo
Outcome: IBS-Global Improvement Scale response
効果: 19.3% vs 8.9% response at day 28
p=0.048
対象集団: adults with non-constipated irritable bowel syndrome
Meta-Analysis
n=3154
Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable …
Dose: None
vs: placebo
Outcome: quality of life, depression, and anxiety in IBS …
効果: SUCRA=89.7% (B. longum for QoL); SUCRA=95.6% (probiotic combo for depression)
None
対象集団: patients with irritable bowel syndrome
Randomized Controlled Trial
n=61
12 weeks
Double-blind
Four-strain probiotic exerts a positive effect on irritable bowel syndrome symptoms occurring in inflammatory bowel …
Dose: None
vs: Placebo
Outcome: IBS-SSS (100-point reduction)
効果: 45% active vs 33% placebo (P=0.42)
P=0.42
対象集団: IBD patients with IBS symptoms in remission
Randomized Controlled Trial
4 weeks
Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group …
Dose: 2 g
vs: Placebo
Outcome: Constipation symptoms
効果: None
P = 0.005
対象集団: IBS patients
Randomized Controlled Trial
12 weeks
Double-blind
Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides …
Dose: None
vs: Placebo
Outcome: Quality of life
効果: None
p = 0.023
対象集団: IBS patients
Other
Computational prediction of new therapeutic effects of probiotics.
Dose: None
vs: None
Outcome: Colitis severity
効果: None
None
対象集団: Crohn's disease patients
Key Statistics
3
研究数
350
参加者数
↑
Positive
B
グレード
Referenced Papers
Journal of gastroenterology …
2026
1 件の引用
European journal of …
2026
World journal of …
2025
2 件の引用
Scientific reports
2024
20 件の引用
Scientific reports
2024
10 件の引用
The Yale journal …
2024
5 件の引用
Journal of clinical …
2024
4 件の引用
Journal of neurogastroenterology …
2024
4 件の引用
International journal of …
2024
2 件の引用
Nutrients
2023
33 件の引用
Anaerobe
2023
14 件の引用
International journal of …
2023
9 件の引用
Minerva pediatrics
2023
2 件の引用
Voprosy pitaniia
2023
Journal of neurogastroenterology …
2022
21 件の引用
Evaluating the Efficacy of Probiotics in IBS Treatment Using a Systematic Review of Clinical Trials and Multi-Criteria Decision Analysis.
Systematic Review
Nutrients
2022
19 件の引用
Gastroenterology research and …
2022
15 件の引用
Microorganisms
2021
47 件の引用
Acta gastro-enterologica Belgica
2021
14 件の引用
Nutrients
2020
99 件の引用
Nutrients
2020
78 件の引用
Digestive and liver …
2020
28 件の引用
Cellular and molecular …
2020
4 件の引用
Probiotics and antimicrobial …
2019
43 件の引用
Effects of probiotic supplementation on post-infectious irritable bowel syndrome in rodent model.
Other
BMC complementary and …
2019
24 件の引用
Diseases (Basel, Switzerland)
2018
50 件の引用
Beneficial microbes
2018
48 件の引用
Saudi journal of …
2018
41 件の引用
Cellular and molecular …
2017
9 件の引用
World journal of …
2016
99 件の引用
Journal of dairy …
2016
67 件の引用
Journal of clinical …
2015
62 件の引用
Journal of gastroenterology …
2014
164 件の引用
Orvosi hetilap
2014
6 件の引用
Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis.
Meta-Analysis
Revista espanola de …
2013
102 件の引用
Scandinavian journal of …
2013
74 件の引用
PloS one
2012
445 件の引用
Journal of clinical …
2012
207 件の引用
Revista de gastroenterologia …
2012
Journal of clinical …
2011
163 件の引用
Alimentary pharmacology & …
2010
4 件の引用
Neurogastroenterology and motility
2009
81 件の引用
Gut and liver
2009
77 件の引用
Digestive diseases and …
2008
160 件の引用
Current opinion in …
2008
68 件の引用
Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors.
Other
Nature medicine
2007
774 件の引用
Minerva gastroenterologica e …
2006
22 件の引用
Journal of clinical …
2004
298 件の引用
Journal of clinical …
2004
205 件の引用
The American journal …
1983
78 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 1-10 billion CFU/day
- ibssupport:
- 10 billion CFU/day for 4-8 weeks
- lactosesupport:
- 1-2 billion CFU with dairy consumption
上限量： Generally well-tolerated up to 20 billion CFU/day
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | 12 weeks | Positive | 200 |
| None | -- | Positive | 3154 |
| None | 12 weeks | Neutral | 61 |
| 2 g | 4 weeks | Mixed | -- |
| None | 12 weeks | Positive | -- |
| None | -- | Neutral | -- |
| 10^9 CFU L. acidophilus LA-5 + L. paracasei daily | 12 weeks | Positive | 110 |
| None | -- | Positive | -- |
推奨摂取タイミング： On an empty stomach or before meals; may also be taken with dairy
Safety & Side Effects
報告されている副作用
- ⚠ Mild gas and bloating during initial use
- ⚠ Occasional loose stools
- ⚠ Rare allergic reactions in dairy-sensitive individuals (dairy-cultured strains)
- ⚠ Very rare: bacteremia in immunocompromised individuals
既知の相互作用
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
- ● Sulfasalazine (may affect bacterial metabolism)
耐容上限摂取量： Generally well-tolerated up to 20 billion CFU/day
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Lactobacillus acidophilus help with Irritable Bowel Syndrome (IBS)?
Based on 3 studies with 350 participants, there is moderate evidence from clinical studies that Lactobacillus acidophilus may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Lactobacillus acidophilus should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus acidophilus?
Reported side effects may include Mild gas and bloating during initial use, Occasional loose stools, Rare allergic reactions in dairy-sensitive individuals (dairy-cultured strains), Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus acidophilus and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 350 total participants. The overall direction of effect is positive.
Related Evidence
に関する他の成分： Irritable Bowel Syndrome (IBS)
References
- [1] Uday C Ghoshal et al.. J Gastroenterol Hepatol. 2026. Probiotic Blend of Lactobacillus acidophilus LA-5 and Bifidobacterium animalis ssp. Lactis BB-12 in Non-constipated Irritable Bowel Syndrome: A Double-Blind Randomized … doi:10.1111/jgh.70137 PubMed
- [2] Theodore Rokkas et al.. Eur J Gastroenterol Hepatol. 2026. Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable bowel syndrome: a systematic review … doi:10.1097/MEG.0000000000003062 PubMed
- [3] Anne Fennessy et al.. World J Gastrointest Pharmacol Ther. 2025. Four-strain probiotic exerts a positive effect on irritable bowel syndrome symptoms occurring in inflammatory bowel diseases in absence of inflammation … doi:10.4292/wjgpt.v16.i2.101268 PubMed
- [4] Marlynna Sarkawi et al.. Sci Rep. 2024. A randomized, double-blinded, placebo-controlled clinical trial on Lactobacillus-containing cultured milk drink as adjuvant therapy for depression in irritable bowel syndrome. doi:10.1038/s41598-024-60029-2 PubMed
- [5] Sadegh Sulaimany et al.. Sci Rep. 2024. Computational prediction of new therapeutic effects of probiotics. doi:10.1038/s41598-024-62796-4 PubMed
- [6] Mattia Tinazzi et al.. Yale J Biol Med. 2024. Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal Extracts in an In Vitro … doi:10.59249/JOMF5336 PubMed
- [7] Anita Gąsiorowska et al.. J Clin Med. 2024. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel … doi:10.3390/jcm14010006 PubMed
- [8] Young Hoon Chang et al.. J Neurogastroenterol Motil. 2024. Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study. doi:10.5056/jnm23036 PubMed
- [9] Lena Capirchio et al.. Int J Mol Sci. 2024. A Synbiotic Combining Chitin-Glucan and Lactobacillus acidophilus NCFM Induces a Colonic Molecular Signature Soothing Intestinal Pain and Inflammation in an … doi:10.3390/ijms251910732 PubMed
- [10] Peiwei Xie et al.. Nutrients. 2023. Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. doi:10.3390/nu15173856 PubMed
- [11] Arzu Hizay et al.. Anaerobe. 2023. Lactobacillus acidophilus regulates abnormal serotonin availability in experimental ulcerative colitis. doi:10.1016/j.anaerobe.2023.102710 PubMed
- [12] Ludovic D Langlois et al.. Int J Mol Sci. 2023. Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability in a Chronic-Restraint Stress Model. doi:10.3390/ijms24087220 PubMed
- [13] Veronica Cocetta et al.. Minerva Pediatr (Torino). 2023. Maintenance of intestinal epithelial barrier integrity by a combination of probiotics, herbal extract, and vitamins. doi:10.23736/S2724-5276.23.07128-8 PubMed
- [14] V N Drozdov et al.. Vopr Pitan. 2023. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea … doi:10.33029/0042-8833-2023-92-4-92-103 PubMed
- [15] Seung Yong Shin et al.. J Neurogastroenterol Motil. 2022. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: … doi:10.5056/jnm21202 PubMed
- [16] Cecilia Ceccherini et al.. Nutrients. 2022. Evaluating the Efficacy of Probiotics in IBS Treatment Using a Systematic Review of Clinical Trials and Multi-Criteria Decision Analysis. doi:10.3390/nu14132689 PubMed
- [17] Jin Lee et al.. Gastroenterol Res Pract. 2022. Clinical Efficacy of Probiotic Therapy on Bowel-Related Symptoms in Patients with Ulcerative Colitis during Endoscopic Remission: An Observational Study. doi:10.1155/2022/9872230 PubMed
- [18] Luisa Marras et al.. Microorganisms. 2021. The Role of Bifidobacteria in Predictive and Preventive Medicine: A Focus on Eczema and Hypercholesterolemia. doi:10.3390/microorganisms9040836 PubMed
- [19] N Md Mokhtar et al.. Acta Gastroenterol Belg. 2021. Clinical assessment and cytokines level in constipation-predominant irritable bowel syndrome participants treated with Lactobacillus-containing cultured milk drink. doi:10.51821/84.4.009 PubMed
- [20] Christopher J Martoni et al.. Nutrients. 2020. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. doi:10.3390/nu12020363 PubMed
- [21] Barbara Skrzydło-Radomańska et al.. Nutrients. 2020. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant … doi:10.3390/nu12071999 PubMed
- [22] Stéphane Sadrin et al.. Dig Liver Dis. 2020. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. doi:10.1016/j.dld.2019.12.009 PubMed
- [23] Jean Michel Maixent et al.. Cell Mol Biol (Noisy-le-grand). 2020. Clinical effects of Lactobacillus strains as probiotics in the treatment of irritable bowel syndrome. Results from the LAPIBSS trial: Future … PubMed
- [24] Konstantinos Leventogiannis et al.. Probiotics Antimicrob Proteins. 2019. Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. doi:10.1007/s12602-018-9401-3 PubMed
- [25] Ki-Bae Hong et al.. BMC Complement Altern Med. 2019. Effects of probiotic supplementation on post-infectious irritable bowel syndrome in rodent model. doi:10.1186/s12906-019-2610-9 PubMed
- [26] Mary Scriven et al.. Diseases. 2018. Neuropsychiatric Disorders: Influence of Gut Microbe to Brain Signalling. doi:10.3390/diseases6030078 PubMed
- [27] K Preston et al.. Benef Microbes. 2018. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. doi:10.3920/BM2017.0105 PubMed
- [28] Ya-Nan Cao et al.. Saudi J Gastroenterol. 2018. Lactobacillus acidophilus and Bifidobacterium longum supernatants upregulate the serotonin transporter expression in intestinal epithelial cells. doi:10.4103/sjg.SJG_333_17 PubMed
- [29] S Sadrin et al.. Cell Mol Biol (Noisy-le-grand). 2017. Lactobacillus acidophilus versus placebo in the symptomatic treatment of irritable bowel syndrome: the LAPIBSS randomized trial. doi:10.14715/cmb/2017.63.9.21 PubMed
- [30] Anna Lyra et al.. World J Gastroenterol. 2016. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. doi:10.3748/wjg.v22.i48.10631 PubMed
- [31] Bojana Bogovič Matijašić et al.. J Dairy Sci. 2016. Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of … doi:10.3168/jds.2015-10743 PubMed
- [32] Hyuk Yoon et al.. J Clin Biochem Nutr. 2015. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a … doi:10.3164/jcbn.15-14 PubMed
- [33] Jun Sik Yoon et al.. J Gastroenterol Hepatol. 2014. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. doi:10.1111/jgh.12322 PubMed
- [34] János Fehér et al.. Orv Hetil. 2014. [Correlation of the microbiota and intestinal mucosa in the pathophysiology and treatment of irritable bowel, irritable eye, and irritable mind … doi:10.1556/OH.2014.29987 PubMed
- [35] María Ortiz-Lucas et al.. Rev Esp Enferm Dig. 2013. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. doi:10.4321/s1130-01082013000100005 PubMed
- [36] Luise Mølenberg Begtrup et al.. Scand J Gastroenterol. 2013. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial. doi:10.3109/00365521.2013.825314 PubMed
- [37] Marina L Ritchie et al.. PLoS One. 2012. A meta-analysis of probiotic efficacy for gastrointestinal diseases. doi:10.1371/journal.pone.0034938 PubMed
- [38] Bong Ki Cha et al.. J Clin Gastroenterol. 2012. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, … doi:10.1097/MCG.0b013e31823712b1 PubMed
- [39] Javier Diaz Ferrer et al.. Rev Gastroenterol Peru. 2012. [Probiotic supplement (Lactobacillus acidophilus and bulgaricus) utility in the treatment of irritable bowel syndrome]. PubMed
- [40] Tamar Ringel-Kulka et al.. J Clin Gastroenterol. 2011. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional … doi:10.1097/MCG.0b013e31820ca4d6 PubMed
- [41] A C Ford. Aliment Pharmacol Ther. 2010. Probiotics in irritable bowel syndrome: underachievers or underpowered? doi:10.1111/j.1365-2036.2009.04223.x PubMed
- [42] L Ohman et al.. Neurogastroenterol Motil. 2009. B-cell activation in patients with irritable bowel syndrome (IBS). doi:10.1111/j.1365-2982.2009.01272.x PubMed
- [43] Kyoung Sup Hong et al.. Gut Liver. 2009. Effect of probiotics on symptoms in korean adults with irritable bowel syndrome. doi:10.5009/gnl.2009.3.2.101 PubMed
- [44] Dong Hyun Sinn et al.. Dig Dis Sci. 2008. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. doi:10.1007/s10620-007-0196-4 PubMed
- [45] Eamonn M M Quigley. Curr Opin Pharmacol. 2008. Probiotics in functional gastrointestinal disorders: what are the facts? doi:10.1016/j.coph.2008.08.007 PubMed
- [46] Christel Rousseaux et al.. Nat Med. 2007. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. doi:10.1038/nm1521 PubMed
- [47] M Astegiano et al.. Minerva Gastroenterol Dietol. 2006. Treatment of irritable bowel syndrome. A case control experience. PubMed
- [48] Thomas J Borody et al.. J Clin Gastroenterol. 2004. Bacteriotherapy using fecal flora: toying with human motions. doi:10.1097/01.mcg.0000128988.13808.dc PubMed
- [49] Alfredo Saggioro. J Clin Gastroenterol. 2004. Probiotics in the treatment of irritable bowel syndrome. doi:10.1097/01.mcg.0000129271.98814.e2 PubMed
- [50] A D Newcomer et al.. Am J Clin Nutr. 1983. Response of patients with irritable bowel syndrome and lactase deficiency using unfermented acidophilus milk. doi:10.1093/ajcn/38.2.257 PubMed
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。